| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
NOT Receptor Modulator 1 targets nuclear receptor Nurr-1/NOT (also known as nuclear hormone receptor 4A/NR4A). These receptors are involved in the regulation of gene expression and play roles in inflammation, autoimmune disorders, and cancer. By modulating the activity of these receptors, the compound can influence cellular signaling pathways involved in these diseases.
|
|---|---|
| ln Vitro |
In vitro, NOT Receptor Modulator 1 acts as a modulator of nuclear receptor NOT. Its activity has been characterized in cell-based assays, demonstrating its ability to modulate NOT receptor signaling. The compound is primarily used in biomedical research to investigate the therapeutic potential of NOT receptor signaling in diseases such as inflammation, autoimmune disorders, and cancer.
|
| ln Vivo |
In vivo, NOT Receptor Modulator 1 is used in research to study the role of NOT receptors in disease models. Its potential therapeutic applications include inflammation, autoimmune disorders, and cancer. Detailed in vivo studies are needed to fully characterize its pharmacological effects and therapeutic potential. The compound is not approved for clinical use.
|
| Enzyme Assay |
For in vitro receptor binding assays, NOT Receptor Modulator 1 is evaluated for its ability to bind to NOT receptors (Nurr-1/NR4A). Radiolabeled or fluorescently labeled ligands can be used in competitive binding assays with membrane preparations or purified receptor proteins. Binding affinity (Ki or Kd) is calculated from saturation or competition binding curves.
|
| Cell Assay |
For in vitro cell-based assays, NOT Receptor Modulator 1 is tested on cells expressing NOT receptors. Cells are treated with the compound at various concentrations (typically 1 nM-10 µM) for 24-72 hours. Receptor activity is measured by assessing target gene expression using qPCR or reporter gene assays. Cell viability and proliferation are assessed using MTT assays. Inflammatory cytokine production can be measured by ELISA.
|
| Animal Protocol |
For in vivo animal experiments, NOT Receptor Modulator 1 is typically administered orally or intraperitoneally to mouse models of inflammation, autoimmune disease, or cancer. The compound is given at doses ranging from 1-50 mg/kg for 1-4 weeks. Disease severity is assessed using appropriate clinical scores, histopathological analysis, and biochemical markers. Inflammatory cytokine levels are measured in serum or tissue samples.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for NOT Receptor Modulator 1 are limited. As a small molecule with a molecular weight of 362.85 g/mol and formula C₂₂H₁₉ClN₂O, it is expected to have moderate oral bioavailability. The compound is likely metabolized in the liver via cytochrome P450 enzymes. Standard pharmacokinetic studies would be required to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for NOT Receptor Modulator 1 are limited. As a research compound, comprehensive toxicological studies have not been extensively reported. The compound is classified as a research-grade reagent and is not for human therapeutic use. Standard laboratory safety practices should be followed when handling.
|
| Additional Infomation |
NOT Receptor Modulator 1 is a research-use only compound and has not been approved for clinical applications. It is also known as a nuclear hormone receptor 4A/NR4A modulator. Its molecular weight is 362.85, and its formula is C₂₂H₁₉ClN₂O. The compound is used in research on nuclear receptor signaling and its role in inflammation, autoimmune disorders, and cancer. It is available from various research chemical suppliers.
|
| Molecular Formula |
C22H19CLN2O
|
|---|---|
| Molecular Weight |
362.852064371109
|
| Exact Mass |
362.118
|
| CAS # |
1015231-98-7
|
| PubChem CID |
24759785
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Index of Refraction |
1.632
|
| LogP |
5.52
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
477
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C=CC(=CC=1)C1=CN2C(C=CC(=C2)C2=CC=CC(=C2)C(C)(C)O)=N1
|
| InChi Key |
YQUSXNRKHZXSGH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H19ClN2O/c1-22(2,26)18-5-3-4-16(12-18)17-8-11-21-24-20(14-25(21)13-17)15-6-9-19(23)10-7-15/h3-14,26H,1-2H3
|
| Chemical Name |
2-[3-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-6-yl]phenyl]propan-2-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~344.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7560 mL | 13.7798 mL | 27.5596 mL | |
| 5 mM | 0.5512 mL | 2.7560 mL | 5.5119 mL | |
| 10 mM | 0.2756 mL | 1.3780 mL | 2.7560 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
